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Background/aim: In the differential diagnosis of hirsutism, early follicular basal 17-OH-progesterone levels sometimes overlap with the
diagnosis of late onset congenital adrenal hyperplasia (LOCAH) and other causes of hyperandrogenism. This study aims to investigate
the role of some common tests and clinical findings in differential diagnosis in such cases.
Materials and methods: One hundred seventy-five female patients with hirsutism and mildly high initial 17-OH-progesterone levels
(2-10 ng/mL) were included in the study. The cases were divided into three groups according to their diagnosis: LOCAH (n = 16, mean
age = 26.1 ± 6.9), polycystic ovary syndrome (PCOS) (n = 122, mean age = 23.9 ± 5.1), and intracranial hypertension (IH) (n = 37, mean
age = 25.2 ± 7.3). Clinical signs and symptoms, such as menstrual irregularity and hirsutism score, and hormone levels including total
testosterone and dehydroepiandrosterone sulfate (DHEAS), were compared between the groups.
Results: There was no difference between the groups with PCOS, LOCAH, and IH for total testosterone level results (P = 0.461). The
DHEAS level was higher in the PCOS group than in the LOCAH group (449.6 ± 151.14 vs. 360.31 ± 152.40, P = 0.044). While there
was no difference between the PCOS and LOCAH groups in terms of menstrual irregularity (P = 0.316), the hirsutism score for IH was
significantly lower than those of PCOS and LOCAH (9.2 vs. 12.2 and 11.1, respectively; P < 0.001). Basal 17-OH-progesterone levels
were higher in the LOCAH group than in the other groups (P = 0.016).
Conclusion: While DHEAS level was lower in LOCAH than in PCOS, it was not different from that in IH. While the severity of
hirsutism was higher in LOCAH than in IH, it was not different from that in PCOS. Menstrual irregularity was similar between PCOS
and LOCAH. According to these results, although the auxiliary tests and clinical findings for the diagnosis of LOCAH contribute to the
clinical interpretation, they are not superior to the 17-OH-progesterone level for diagnosis.
Key words: Late-onset congenital adrenal hyperplasia (LOCAH), polycystic ovary syndrome (PCOS), 17-OH-progesterone,
dehydroepiandrosterone sulphate (DHEAS), idiopathic hyperandrogenism (IH)

1. Introduction
Hirsutism is defined as male pattern hair growth in
women. It affects an average of 5%–10% of women
of reproductive age [1]. This situation can be a
source of emotional stress that can affect daily life
[2,3]. Hirsutism is a result of the interaction between
circulating serum androgens and the sensitivity of hair
follicles to these hormones. Increased serum androgen
concentrations are defined as hyperandrogenism,
which can cause hirsutism, acne, androgenic
alopecia, and even virilization. The excessive growth
of terminal hair in women in a male-like pattern
is the most common clinical diagnostic finding of
hyperandrogenism [4,5]. Although polycystic ovary
syndrome (PCOS) constitutes 75%–80% of cases, there

are many underlying causes of etiology in patients
with hirsutism [6]. These causes can be serious clinical
conditions such as androgen-secreting tumors and
ovarian hyperthecosis, as well as Cushing syndrome,
hyperprolactinemia, thyroid disorders, HAIR-AN
syndrome, late-onset congenital adrenal hyperplasia
(LOCAH), and idiopathic hyperandrogenism (IH)
[7,8]. In the differential diagnosis, along with menstrual
cycle pattern, laboratory methods are used, including
measuring levels of human chorionic gonadotropin
(hCG), prolactin, follicle-stimulating hormone (FSH),
thyroid-stimulating hormone (TSH), and early
morning 17-hydroxyprogesterone (performed around
8:00 AM). Imaging methods may be used when further
investigation is required.
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LOCAH (or nonclassical congenital adrenal
hyperplasia) accounts for less than 5% of all causes of
hirsutism. However, 60% of adult women diagnosed
with LOCAH also have hirsutism. More than 90% of all
congenital adrenal hyperplasia cases have a defect in the
conversion of 17-hydroxyprogesterone to 11-deoxycortisol.
The enzyme that performs this reaction is 21-hydroxylase,
and the activity level of this enzyme is 20%–50% in
LOCAH [9–12]. Measuring 17-hydroxyprogesterone
concentration, the substrate of the missing enzyme, is
the screening method used in diagnosis. For the first
screening, if the woman has regular menstrual cycles, the
serum samples should be taken in the morning (07:30
to 8:00) for 17-hydroxyprogesterone concentration
during the follicular phase of the menstrual cycle. For
women with irregular menses, samples can be drawn on
a random day. Generally, a basal 17-hydroxyprogesterone
value greater than 2 ng/mL (6 nmol/L) is sufficient for
LOCAH diagnosis; however, the threshold value has
been accepted as >10 ng/mL for definitive laboratory
diagnosis. For moderate elevations in the 2–10 ng/mL
range, the ACTH stimulation test (high dose, 250 mcg) is
used for confirmation. Cases with 17-OH-progesterone
levels higher than 10 ng/mL in response to the ACTH
stimulation test are considered LOCAH [13]. Although
the use of a genetic test is not necessary for the initial test,
it should be used for genetic counseling before conception
in the case of borderline laboratory values [9,11].
In this study, the importance of auxiliary laboratory
tests and some clinical findings in the differential diagnosis
of LOCAH was investigated in hirsute women whose basal
17-hydroxyprogesterone level was found to be slightly
high.

Sakarya University Ethics Committee.

2. Materials and methods
2.1 Subjects
This is a retrospective study in which data from July
2017 to December 2019 were scanned. One hundred and
seventy-five female patients of reproductive age admitted
to the endocrinology outpatient clinic due to increased
hairiness and whose baseline 17-OH-progesterone level
was found to be high at the limit were included in the
study. The mean (±SD) age of the patients included in the
study was 24.4 (±5.8). The age range was 18–48. Women
under the age of 18 and postmenopausal women were
excluded from the study. Demographic data, menstrual
irregularity, and infertility history were recorded. All
patients were also questioned regarding the use of
pharmacological drugs such as glucocorticoid, due to the
possibility of false negative results due to the inhibition
of the corticotropic axis. There were no patients using
this type of medication. Local ethics committee approval
(Ref. No.: 71522473/050.01.04/42) was obtained from the

2.3 Definition of LOCAH
Basal 17-OH-progesterone levels of greater than 10 ng/mL
were considered diagnostic criteria of LOCAH, while basal
17-OH-progesterone levels between 2–10 ng/mL were
accepted as a mildly high limit. A high-dose (250 mcg)
ACTH stimulation test was performed for all patients with
basal values of 2–10 ng/mL. At 30, 60, 120, and 180 min
after intramuscular ACTH injection, 17-OH-progesterone
levels were measured from blood samples taken through
a catheter placed intravenously. When any of these results
were higher than 10 ng/mL, the result was interpreted as
LOCAH. Genetic consultation for the confirmation of the
genotyping of the CYP21A2 gene was recommended for
all patients with test results greater than 10 ng/mL.

2.2 Auxiliary diagnostic methods
In the laboratory evaluation, serum total testosterone and
DHEAS (dehydroepiandrosterone sulfate) levels were
measured. Serum samples for laboratory examination
were taken at the beginning of the cycle and early in
the morning. The chemiluminescent microparticle
immunotherapy (CMIA) method and radioimmunoassay
(RIA) were used for DHEAS (Architect DHEA-S Kit;
Abbott Architect I2000SR [autoanalyzer], Abbott
Laboratories, Abbott Park, IL, USA) and total testosterone
measurement (Architect 2nd Generation Testosterone
Kit; Abbott Architect I2000SR [autoanalyzer, Abbott
Laboratories, Illinois, IL, USA]), respectively. Additionally,
transabdominal ultrasonographic examination was
performed for evaluation of gynecological anatomical
structures and possible PCOS diagnosis.
As the clinical auxiliary diagnostic method, the degree
of hirsutism and menstrual patterns were evaluated.
Oligomenorrhea was defined as having more than 35 days
of menstrual intervals, while amenorrhea was defined
as the condition of having no more than 6 months of
menstruation consecutively. Hirsutism was determined
according to the Modified Ferriman Gallwey Scoring
System. Total scores of 8 or more on 9 different body
surfaces obtained by inspection were defined as hirsutism.
All cases included in the study were grouped and
compared according to the identified LOCAH (n = 16),
PCOS (n = 122), and IH (n = 37) diagnoses. The Endocrine
Society Clinical Practice Guidelines were used as a guide
for the diagnosis of PCOS [14]. The absence of menstrual
irregularity and lack of PCOS appearance on ultrasound
was considered sufficient for the diagnosis of IH.

2.4 Statistical analysis
Data analysis was performed by using SPSS-22 for
Windows (Statistical Package for Social Science, SPSS
Inc., Chicago IL, USA). The variables were investigated
using visual methods (histograms, probability plot) and
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analytical methods (Kolmogorov–Smirnov and Shapiro–
Wilk tests) to determine whether or not they were
normally distributed. We performed analyses to describe
and summarize the distributions of variables. Continuous
variables were reported as mean ± standard deviation and
as whole number and percentages for categorical variables.
One-way ANOVA test was used to compare multiple
groups. One-way ANOVA followed by Duncan’s multiple
comparison of the means revealed significant differences
between the groups. We used the Kruskal–Wallis test to
compare continuous nonparametric variables. The Mann–
Whitney U test was performed for the double comparisons.
The chi-square test (since the expected cell counts were
sufficiently high) was used to compare the proportions
in different groups. The statistically significant two-tailed
P-value was determined to be <0.05.
3. Results
The mean values of modified FGS, total testosterone,
DHEAS, and basal 17-OH-progesterone levels were 11.5 ±
3.5, 44.7 ± 15.5 ng/dL, 431.8 ± 153.0 mcg/dL, and 3.47 ± 1.16
ng/mL, respectively. Menstrual irregularity was present in
43.4% of all patients. Descriptive data are summarized in
Table 1. According to the ACTH stimulation test result,
17-OH-progesterone response was higher than 10 ng/mL
in 16 (9.1%) patients. In 4 patients, the response was over
15 ng/mL. The diagnosis was confirmed by genetic analysis
in 9 of 16 patients. All patients with positive genetic results
had a mutation in the CYP21A2 gene. The remaining 7
patients did not want to undergo genetic analysis or denied
for economic reasons. According to all evaluation results,
16 (9.1%) of the patients were accepted as having LOCAH,
37 (21.1%) IH, and 122 (69.7%) PCOS.
There was no difference between the groups in terms
of average age. In the comparative analysis between the
diagnostic groups, the mean DHEAS level was statistically
different between the groups (P = 0.04) (Figure A). This
difference was between LOCAH and PCOS according to
post-hoc analysis (360.3 vs. 449.6, respectively; P = 0.044).
There was no difference between the groups in terms of
total testosterone levels (P = 0.461) (Figure B). When
evaluated in terms of modified FGS, while there was no
difference between LOCAH and PCOS (P = 0.146), IH
was significantly lower than the other groups (P < 0.001)
(Figure C). When basal 17-OH-progesterone levels were
compared, the results were statistically significantly higher
in LOCAH than in the other groups (P = 0.016) (Table 2).
However, this difference was more pronounced between
LOCAH and IH (4.70 vs. 3.17, respectively; P = 0.006).
When compared in terms of menstrual irregularity,
no statistically significant difference was found between
LOCAH (62.5%) and PCOS (49.2%, P = 0.316). As
expected, there were no menstrual irregularities in IH for
diagnosis.
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Table 1. Baseline characteristics of patients.
Variables

Results*

Age, years

24.4 (±5.8)

Ferriman–Gallweyscore

11.5 (3.5)

Basal 17-OH-progesterone, ng/ml

3.47 (±1.16)

Total testosterone, ng/dL

44.7 (±15.5)

DHEAS , mcg/dL

431.8 (±153.0)

Menstrualirregularity, n (%)

76 (43.4)

FSH, IU/L

4.79 (±1.81)

LH, IU/L

5.89 (±4.80)

Oestradiol, pg/mL

46.9 (±51.8)

PRL, mcg/L

20.5 (±11.7)

SD: standard deviation, DHEAS: dehydroepiandrosterone
sulfate, LOCAH: lateonsetcongenital adrenal hyperplasia, PCOS:
polycystic ovary syndrome, FSH: follicle-stimulating hormone,
LH: luteinizing hormone, PRL: prolactin.
*Descriptive results for continuous variables were expressed as
mean and standard deviation.

4. Discussion
In this study, we tested differential diagnosis for women
with hirsutism with basal 17-OH-progesterone levels >2
ng/mL using serum DHEAS, serum testosterone levels,
hirsutism score, and menstrual cycle characteristics
without the need for an ACTH stimulation test. However,
according to our results, laboratory features and clinical
findings of patients with LOCAH were not particularly
different from those of the other diagnoses.
Hirsutism is a clinical reflection of hyperandrogenism.
Although the most common cause is PCOS, many reasons
that may be benign or malignant can be considered in
differential diagnosis [7,8]. In hirsutism, abnormalities of
adrenal functions are found quite frequently. The clinical
appearance of LOCAH, which develops due to enzyme
deficiencies such as adrenal 21 alpha hydroxylase, may be
indistinguishable from the clinical appearances of other
forms of hyperandrogenemia, such as PCOS and IH [15].
Since the ovarian sonographic features and their responses
to the same treatment are similar, the differential diagnosis
of PCOS and LOCAH can be confused [16,17]. In some
studies, patients with hirsutism diagnosed with IH and
PCOS were diagnosed with LOCAH as a result of further
examination [15]. Although LOCAH has a low incidence,
the Endocrine Society Clinical Practice Guidelines
recommends LOCAH screening for differential diagnosis
in all patients with hyperandrogenemia [14].
In some ethnic groups such as Ashkenazi Jews,
Mediterraneans, and Hispanics, the incidence of
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Figure. Summary of the comparison of DHEAS (A), total testosterone (B) and modified FGS (C) among the
diagnostic groups.

LOCAH in the general population can be observed at
high rates of 1.9% to 3.7% [18]. Therefore, LOCAH
should be considered in the differential diagnosis of
hyperandrogenism in regions with these ethnic groups.
In women with hyperandrogenemia, the prevalence
of LOCAH is around 5% [8]. While genetic analysis is
required for definitive diagnosis in adrenocortical enzyme
deficiencies, measuring the basal 17-OH-progesterone
level in the early follicular phase and performing the
ACTH stimulation test if necessary are usually sufficient
[13,19,20]. Although there is no fully accepted threshold
value in adult women with hirsutism for the basal 17-OHprogesterone level, a level higher than 2 ng/mL is generally
sufficient for diagnosis. However, values higher than this
limit can overlap with both PCOS and LOCAH. In one
study, basal 17-OH-progesterone levels of between 2–3

ng/mL were found in 19% and 25% of PCOS patients
who were obese and lean, respectively [21]. In the current
study, we selected only patients whose results were higher
than 2ng/mL. Therefore, the role of other clinical and
laboratory features in differential diagnosis is important
before ACTH stimulation testing or genetic analysis
is performed. Similarly, there is no generally accepted
threshold for the 17-OH-progesterone response in the
ACTH stimulation test. Even so, it provides a great deal of
information in distinguishing LOCAH from a diagnosis
of PCOS.
In women with hirsutism, DHEAS, total testosterone,
modified FGS, and menstrual cycle query are routinely
used for differential diagnosis. In adult women, 50%–60%
of the circulating testosterone hormone is derived from
the conversion of androstenedione in the liver under
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Table 2. Summary of the comparison of age, DHEAS, total testosterone, basal 17-OH-progesterone, and Ferriman–
Gallwey scores among the diagnostic groups.
Results*
Variables

LOCAH
(n = 16)

PCOS
(n = 122)

IH
(n = 37)

P value

Age, years

26.1 (±6.9)

23.9 (±5.1)

25.2 (±7.3)

0.317

DHEAS, mcg/dL

360.3†† (±152.4)

449.6†† (±151.1)

403.9 (±150.0)

0.040

Total testosterone, ng/dL

47.2 (±20.5)

45.0 (±15.2)

42.7 (±14.4)

0.461

Basal 17-OH-progesterone, ng/mL

4.70† (±2.17)

3.40 (±0.96)

3.17 (±0.85)

0.016

Ferriman–Gallwey Score

11.1 (±3.3)

12.2 (±3.6)

9.2† (±2.1)

<0.001

Menstrual irregularity , n (%)

10 (62.5)

60 (49.6)

-†

<0.001

SD: standard deviation, DHEAS: dehydroepiandrosterone sulfate, LOCAH: lateonsetcongenital adrenal hyperplasia,
PCOS: polycystic ovary syndrome, FSH: follicle-stimulating hormone, LH: luteinizing hormone, PRL: prolactin.
*Descriptive results for continuous variables were expressed as mean and standard deviation.
*Continuous variables were expressed as mean ± standard deviation, categorical variables were expressed as
percentage and frequency.
†This sign indicates that the difference is only within this group. ††There is a difference between the groups
marked with this sign.

the action of 17b-hydroxysteroid dehydrogenase type 5
enzyme, while 25%–30% are from an ovarian source. The
remaining 10%–15% of serum testosterone is produced
directly from the adrenal cortex and released into the
circulation [22,23]. In studies comparing LOCAH with
other causes of hyperandrogenemia, higher testosterone
levels have been reported in patients with LOCAH [7,24].
However, in one such study, it was reported that the mean of
the modified FGS of all patients with hyperandrogenemia
was between 16–18 and the baseline 17-OH-progesterone
average in the LOCAH group was 14.9 ng/mL [21].
Compared to our study, it can be observed that our patients
have lower clinical and laboratory results. Regardless, our
total testosterone results were similar across all groups.
Under typical physiological conditions, 20%–30%
of free DHEA in serum and almost all of DHEAs are of
adrenal cortex origin [23]. Its production decreases with
age, especially after the age of 30. The main mechanism
that determines the amount in serum is 17,20 lyase
(CYP17) enzyme activity [25]. In one study, 23 patients
with LOCAH were compared with 27 healthy controls and
54 obese and 52 lean patients with PCOS, respectively. The
mean of DHEAS in patients with LOCAH was 322 mcg/
dL, and the results were 235 mcg/dL, 271 mcg/dL, and
248 mcg/dL in the compared groups, respectively [21].
Although the result was statistically significantly higher, the
mean 17-OH-progesterone of LOCAH patients included
in the study was recorded as 14.9 ng/mL. Additionally,
the initial 17-OH-progesterone mean value of the patients
with LOCAH in our study was 4.70 ng/mL, and the
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DHEAS level was surprisingly lower than that of the PCOS
group. The reason for this result may be because the PCOS
patients we selected had lower insulin levels (or insulin
resistance), or the enzyme levels of our LOCAH patients
were slightly better. In another study, the mean DHEAS of
18 patients with LOCAH was statistically higher than that
of PCOS patients (348.5 vs. 235) [7]. However, information
about basal 17-OH-progesterone levels was not obtained
in this study. In addition, a negative correlation has been
demonstrated between insulin resistance and DHEAS
levels in PCOS patients [23]. This is explained by the fact
that the activity of the enzyme CYP17 decreases with
insulin resistance. Since high insulin resistance in PCOS is
a very common feature, it reduces the usability of DHEAS
level in differential diagnosis in such patients.
In the literature, oligoamenorrhea rates have been
reported as between 52%–100% in PCOS patients and
23%–88.9% in LOCAH patients [15,23,24]. In our study,
although the rate in PCOS patients was slightly lower than
that in the literature, there was no significant difference
between LOCAH and PCOS patients. Regardless of serum
androgen levels, the hirsutism score was similar in LOCAH
and PCOS patients, but lower in patients with IH than in
the other groups. These results may indicate that the cases
included in the study are not homogeneously distributed
according to the clinical severity of their disease.
The current study has a number of limitations. First,
there is a known negative correlation between DHEAS
level and insulin resistance in PCOS. However, since we
did not test insulin resistance in most patients, we could
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not evaluate this aspect. Second, we were not able to
confirm all of our patients genetically. Therefore, ACTH
stimulation test results were the main determinants for
diagnosis.
In conclusion, the diagnosis of LOCAH is still a
hormonally demanding process, as it requires genetic
confirmation and counseling, especially in many patients
whose enzyme activity is not very low. In this study, we
investigated whether the diagnosis of LOCAH can be
predicted by routine auxiliary tests and clinical findings
without the need for the ACTH stimulation test. However,
according to our results, although the auxiliary tests and
clinical findings for the diagnosis of LOCAH contribute to

the clinical interpretation, they are not superior to the use
of the 17-OH-progesterone level for diagnosis.
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